**Specifications Table**TableSubject areaBiologyMore specific subject areaDevelopmental/Stem cell biologyType of dataFigure (clustering), graph, tableHow data was acquiredcDNA microarrays using GPL6246 \[MoGene-1_0-st\] Affymetrix Mouse Gene 1.0 ST Array \[transcript (gene) version\]. Organism: *Mus Musculus.* Strain background: C57BL6. Developmental stage: E15.5. Tissue: Fetal liver. Cell type: Lineage negative embryonic hematopoietic cells, Genotype: Geminin^wt/wt^ or Geminin ^fl/wt^ (control) [@bib2] and Geminin^fl/ko^ Vav1:iCre [@bib3] (knock out) mouse linesData formatAnalyzed using Genespring v12.5Experimental featuresWild type and embryos lacking Geminin from the hematopoietic stem and progenitor cells (HSPCs); RNA from HSPCs; HSCPs were isolated using FACS sorting from dissected fetal liversData source locationDepartment of Physiology, Medical School, University of Patras, GreeceData accessibilityThe data within this article and is publicly available at the Gene Expression Omnibus (GEO) under accession GEO: GSE53056.

**Value of the data**•Transcriptomics analysis of embryonic hematopoietic stem and progenitor cells that lack Geminin expression is described.•The present dataset relates to defective hematopoiesis with a differentiation block early in the hematopoietic hierarchy. It is anticipated that similar phenotypes can be interpreted using comparative analyses with our data.•Moreover, the list of differentially expressed genes includes changes in transcription factors and epigenetic regulators that can link Geminin, a cell cycle inhibitor, with novel cellular pathways.•Finally, this dataset can serve as a reference point for various studies pertaining to hematopoietic cell lineage commitment/differentiation and hematopoietic malignancies.

1. Data {#s0005}
=======

Here we present a qualitative evaluation of microarray data in the format of heatmaps, following hierarchical clustering analysis ([Fig. 1](#f0005){ref-type="fig"}). Additionally, we have included a concise set of meta-analyses, both Gene Ontology using DAVID and GSEA ([Fig. 2](#f0010){ref-type="fig"}), as well as a listing of the KEGG pathways ([Table 1](#t0005){ref-type="table"}) affected by the differentially expressed genes [@bib4], [@bib5], [@bib6]. Briefly, the dataset is from whole transcriptome analysis of hematopoietic stem and progenitor cells (HSPCs) isolated from E15.5dpc embryo livers. In this study, control and Geminin knockout littermate embryos were utilized in order to examine the role of Geminin in the developing mouse hematopoietic system. Control were those embryos whose genotype had both Geminin alleles intact, whereas both alleles were disrupted/absent in the Geminin^fl/ko^ Vav1:iCre counterparts in a tissue-specific manner [@bib1], [@bib2].

The transcriptome of both groups was examined by means of cDNA microarrays and differentially expressed genes are presented as fold change of knockout versus control expression levels.

Direct link to deposited files.

<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE53056>

2. Experimental design, materials and methods {#s0010}
=============================================

2.1. Sample preparation {#s0015}
-----------------------

Lineage negative hematopoietic stem and progenitor cells from homogenized fetal livers from E15.5 embryos were isolated by FACS sorting with known blood cell lineage markers (biotinylated CD3, CD8, CD19, B220, Ter119, CD11B, CD11C, GR1; all antibodies were from eBioscience and detection was with APC-conjugated streptavidin).

2.2. RNA extraction {#s0020}
-------------------

Total RNA was extracted from FACS-sorted cells using the RNeasy MicroKit (Qiagen). RNA integrity was assessed with an Agilent 2000 Bioanalyzer.

2.3. Microarray preparation {#s0025}
---------------------------

Samples were enzymatically fragmented and biotinylated using the WT Terminal Labeling Kit (Affymetrix). Samples were hybridized using Affymetrix hybridization kit materials. Washing was done in GeneChip Fluidics Station 450. The chips were scanned using the Affymetrix Scanner 3000 7G with autoloader.

2.4. Microarray data analysis {#s0030}
-----------------------------

The data were processed and analyzed using GeneSpring (v.12.5, Agilent). Statistical significance was assessed using Student׳s *T*-test unpaired (two separate sets of independent and identically distributed samples) with a 95% confidence interval (*P*-value\<0.05). The cutoff value for the fold change of the genes was set to be greater than 1.5. The analysis was carried out using the genotype criterion, but non-averaged for the three biological replicates.

Appendix A. Supplementary material {#s0045}
==================================

Supplementary material
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Supplementary data associated with this article can be found in the online version at <http://dx.doi.org/10.1016/j.dib.2016.03.028>.

![Qualitative evaluation of samples analyzed in the microarrays. Unsupervised hierarchical clustering: the heatmaps provide a qualitative evaluation of the three replicates of each group with regard to their gene expression profiles, the degree of heterogeneity among replicates, and their classification as control versus experimental. The heatmap legend indicates the fold change value range.](gr1){#f0005}

![Gene ontology -- Biological Processes. Among the top hits for biological processes identified by DAVID and GSEA were hematopoiesis, homeostasis, transcription and cell cycle regulation.](gr2){#f0010}

###### 

KEGG Pathways.

Table 1

  **Term**                                         **Gene count**   ***P*-value**
  ------------------------------------------------ ---------------- ---------------
  mmu04630:Jak-STAT signaling pathway              31               9.41E-05
  mmu04070:Phosphatidylinositol signaling system   19               1.98E-04
  mmu04370:VEGF signaling pathway                  18               7.13E-04
  mmu04010:MAPK signaling pathway                  43               7.22E-04
  mmu04640:Hematopoietic cell lineage              19               8.63E-04
  mmu04062:Chemokine signaling pathway             31               0.002207624
  mmu05221:Acute myeloid leukemia                  14               0.002453712
  mmu05340:Primary immunodeficiency                10               0.005878255
  mmu04310:Wnt signaling pathway                   24               0.015019777
  mmu05200:Pathways in cancer                      43               0.025504562
  mmu04620:Toll-like receptor signaling pathway    17               0.02629612
  mmu04020:Calcium signaling pathway               27               0.04331303
